

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM645942

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Marinus Pharmaceuticals, Inc.		05/11/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Oaktree Fund Administration, LLC		
Street Address:	333 S. Grand Avenue, 28th Fl.		
City:	Los Angeles		
State/Country:	CALIFORNIA		
Postal Code:	90071		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Serial Number:	90232607	GAABRYDA	
Serial Number:	90582481	MARINUS	
Serial Number:	90582490		
Serial Number:	90274251		
Serial Number:	90046102	ZTALMY	
CORRESPONDENCE DATA			
Fax Number:	2122919868		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2125584229		
Email:	demarcor@sullcrom.com, nguyenb@sullcrom.com		
Correspondent Name:	Raffaele A. DeMarco		
Address Line 1:	125 Broad Street		
Address Line 2:	Sullivan & Cromwell LLP		
Address Line 4:	New York, NEW YORK 10004-2498		
ATTORNEY DOCKET NUMBER:	018392.00068 (RAD)		
NAME OF SUBMITTER:	Raffaele A. DeMarco		
SIGNATURE:	/Raffaele A. DeMarco/		
DATE SIGNED:	05/11/2021		

OP \$140.00 90232607

Total Attachments: 5

source=Marinus - Trademark Security Agreement (Execution Version)#page1.tif

source=Marinus - Trademark Security Agreement (Execution Version)#page2.tif

source=Marinus - Trademark Security Agreement (Execution Version)#page3.tif

source=Marinus - Trademark Security Agreement (Execution Version)#page4.tif

source=Marinus - Trademark Security Agreement (Execution Version)#page5.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of May [11], 2021 (“**Trademark Security Agreement**”), made by each of the signatories hereto (the “**Trademark Grantors**”), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “**Administrative Agent**”).

W I T N E S S E T H:

WHEREAS, the Trademark Grantors are party to a Security Agreement, dated as May [11], 2021 (the “**Security Agreement**”) in favor of the Administrative Agent, pursuant to which the Trademark Grantors are required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Trademark Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Trademark Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Trademark Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Trademark Grantor or in which such Trademark Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “**Trademark Collateral**”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Trademarks of such Trademark Grantor, including, without limitation, the registered and applied-for Trademarks of such Trademark Grantor listed on **Schedule 1** attached hereto; provided, that no Lien or security interest is granted hereunder with respect to any United States “intent-to-use” trademark or service mark application filed pursuant to Section 1(b) of the Lanham Act prior to the filing of an “Amendment to Allege Use” or a “Statement of Use” pursuant to Sections 1(c) or 1(d) of the Lanham Act, solely to the extent that, and only for so long as, the grant of a security interest therein would impair the validity or enforceability of, render void or voidable, or result in the cancellation of, such “intent-to-use” trademark or service mark application under federal law;

(b) to the extent not covered by **clause (a)**, all income, royalties and other payments now or hereafter due and payable with respect to any of the foregoing;

(c) to the extent not covered by **clause (a)**, the goodwill of the businesses with which the Trademarks are associated; and

(d) to the extent not covered by **clause (a)**, all causes of action for past, present, or future infringement of any of the Trademarks or unfair competition regarding the same.

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Trademark Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Trademark Grantor hereby authorizes and requests that the Commissioner of Trademarks record this Trademark Security Agreement.

THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Remainder of This Page Intentionally Left Blank.]

IN WITNESS WHEREOF, each Trademark Grantor has caused this TRADEMARK SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

TRADEMARK GRANTOR:

MARINUS PHARMACEUTICALS, INC.

By: 

Name: Steven Pfanstiel

Title: Chief Financial Officer

Address for Notices:

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center

100 Matsonford Rd, Suite 500

Radnor, PA 19087

Attn: Steven Pfanstiel, Chief Financial Officer

Tel.: (484) 801-4670

Fax: 484-801-4669

Email: spfanstiel@marinuspharma.com

With a copy to:

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center

100 Matsonford Rd, Suite 500

Radnor, PA 19087

Attn: Martha E. Manning, Esq., General Counsel


Email: mmanning@marinuspharma.com


[Signature Pages to Trademark Security Agreement]

TRADEMARK
REEL: 007288 FRAME: 0826

Accepted and Agreed:
OAKTREE FUND ADMINISTRATION, LLC
as the Administrative Agent

By: Oaktree Capital Management, L.P.
Its: Managing Member



By: _____
DocuSigned by:

3690F206AD0F4E0...
Name: Jessica Dombroff
Title: Vice President

By: _____
DocuSigned by:

597289240E9644E...
Name: Brian Price
Title: Senior Vice President

Address for Notices:
Oaktree Fund Administration, LLC
333 S. Grand Avenue, 28th Fl.
Los Angeles, CA 90071
Attn: Oaktree Agency
Email: Oaktreeagency@alterdomus.com

With a copy to:
Oaktree Capital Management, L.P.
333 S. Grand Avenue, 28th Fl.
Los Angeles, CA 90071
Attn: Aman Kumar
Email: AmKumar@oaktreecapital.com

TRADEMARKSTrademark Registrations and Applications

Trademark	Serial No. (App. No.)	Reg. Date (App. Date)	Owner
GAABRYDA	90/232,607	October 2, 2020	Marinus Pharmaceuticals, Inc.
MARINUS	90/582,481	March 16, 2021	Marinus Pharmaceuticals, Inc.
Overlapping Circle Design 	90/582,490	March 16, 2021	Marinus Pharmaceuticals, Inc.
Wave Design 	90/274,251	October 23, 2020	Marinus Pharmaceuticals, Inc.
ZTALMY	90046102	July 10, 2020	Marinus Pharmaceuticals, Inc.